Short Acting Muscarinic Antagonist (SAMA)
Bronchodilator for the maintenance treatment of bronchospasms associated with COPD and not indicated for the initial treatment of acute episodes of bronchospasms where rescue therapy is required. Also available with albuterol.
Nebulization solution: 500mcg/unit dose t.i.d., q.i.d.
Atrovent HFA MDI: 2 puffs q.i.d.
ipratropium bromide and albuterol
Duoneb 3mls q.i.d.
Combivent, Respimat 2 puffs q.i.d.
Contraindicated in patients with hypersensitivity to ipratropium or atropine.
Closely monitor patients with urinary retention and glaucoma.
FDA pregnancy Category B
Concurrent use with other adgrenergic agents will have additive adgrenergic side effects.
MAOIs and TCA may lead to hypertensive crisis. Beta-blockers may decrease therapeutic effect.
onset: within minutes
peak effect: 1-2 hours
duration: 4-8 hours
elimination: half life 2 hours
Drug Guide for Nurses 11th edition
Integrated Cardiopulmonary Pharmacology 4th edition